Vanderbilt-Ingram website >
The Vanderbilt-Ingram Cancer Center and AstraZeneca have developed a master scientific agreement to streamline and integrate collaborations in basic, translational and clinical cancer research, officials with the company and cancer center announced today.
When 24-year-old Charles Dougherty checks into Vanderbilt-Ingram Cancer Center tomorrow, he’ll be preparing for a treatment that has never been performed before in an adult patient in Nashville, and will be only the second case in Tennessee history.
Initial Results of the Study of Tamoxifen and Raloxifene or STAR, released today revealed the osteoporosis drug raloxifene has been proved to be as effective as tamoxifen in preventing invasive breast cancer.
Researchers at the Vanderbilt-Ingram Cancer Center are studying whether exercise can help curb memory and cognitive problems experienced by many cancer survivors following chemotherapy.
Ginseng, one of the most widely used herbs in traditional Chinese medicine, may improve survival and quality of life after a diagnosis of breast cancer, according to a recent study by Vanderbilt-Ingram Cancer Center researchers. The large epidemiological study, led by Xiao-Ou Shu, M.D., Ph.D., was published online recently in the American Journal of Epidemiology.
A team of researchers at Vanderbilt-Ingram Cancer Center has been awarded $1.5 million from the Susan G. Komen Breast Cancer Foundation.
Accessibility Tools